Coloplast AS's total inventories for the quarter that ended in Mar. 2026 was $610 Mil. Coloplast AS's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $607 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Coloplast AS's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $-18.76.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Coloplast AS's Days Inventory for the
three
months ended in Mar. 2026 was 151.38.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Coloplast AS's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.60.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Coloplast AS's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.55.
Coloplast AS (OTCPK:CLPBF) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Coloplast AS's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Coloplast AS's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Coloplast AS Total Inventories Related Terms
Coloplast AS Total Inventories Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Coloplast AS (CLPBF) has a Total Inventories of $610 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Coloplast AS and its competitors.
Is Coloplast AS's Total Inventories too high?
Coloplast AS's current Total Inventories is $610 Mil. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Total Inventories compare to ISRG and BDX?
Coloplast AS's Total Inventories of $610 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Coloplast AS and its competitors. Coloplast AS's current Total Inventories is $610 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.91, compared to a current price of $57.41 — trading 54.8% below its estimated fair value. The current Total Inventories is $610 Mil. Coloplast AS's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Total Inventories is $610 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $57.41 is trading 54.8% below its estimated GF Value™ of $126.91.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
Total Inventories: $610 Mil
GF Value™: $126.91 vs. price of $57.41 (54.8% below fair value)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
